These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30776014)

  • 1. Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions.
    Ashford JW
    J Alzheimers Dis; 2019; 67(3):923-930. PubMed ID: 30776014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers.
    La AL; Walsh CM; Neylan TC; Vossel KA; Yaffe K; Krystal AD; Miller BL; Karageorgiou E
    J Alzheimers Dis; 2019; 67(3):911-921. PubMed ID: 30689583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.
    Burke SL; Hu T; Spadola CE; Li T; Naseh M; Burgess A; Cadet T
    Sleep Med; 2018 Dec; 52():168-176. PubMed ID: 30359892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian rhythm in Alzheimer disease after trazodone use.
    Grippe TC; Gonçalves BS; Louzada LL; Quintas JL; Naves JO; Camargos EF; Nóbrega OT
    Chronobiol Int; 2015; 32(9):1311-4. PubMed ID: 26376345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone.
    Saletu-Zyhlarz GM; Abu-Bakr MH; Anderer P; Gruber G; Mandl M; Strobl R; Gollner D; Prause W; Saletu B
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):249-60. PubMed ID: 11817501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
    Sultzer DL; Gray KF; Gunay I; Wheatley MV; Mahler ME
    J Am Geriatr Soc; 2001 Oct; 49(10):1294-300. PubMed ID: 11890487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.
    Trillo L; Das D; Hsieh W; Medina B; Moghadam S; Lin B; Dang V; Sanchez MM; De Miguel Z; Ashford JW; Salehi A
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1363-79. PubMed ID: 23707776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone.
    Saletu-Zyhlarz GM; Abu-Bakr MH; Anderer P; Semler B; Decker K; Parapatics S; Tschida U; Winkler A; Saletu B
    Neuropsychobiology; 2001; 44(3):139-49. PubMed ID: 11586054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Sleep Disturbance May Reduce the Risk of Future Probable Alzheimer's Disease.
    Burke SL; Hu T; Spadola CE; Burgess A; Li T; Cadet T
    J Aging Health; 2019 Feb; 31(2):322-342. PubMed ID: 30160576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease.
    Vermeiren Y; Janssens J; Aerts T; Martin JJ; Sieben A; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2016 Jun; 53(3):1079-96. PubMed ID: 27314528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study.
    Camargos EF; Pandolfi MB; Freitas MP; Quintas JL; Lima Jde O; Miranda LC; Pimentel W; Medeiros-Souza P
    Arq Neuropsiquiatr; 2011 Feb; 69(1):44-9. PubMed ID: 21359422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia.
    Schneider LS; Sobin PB
    Psychopharmacol Bull; 1992; 28(1):71-9. PubMed ID: 1351687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease.
    Wharton W; Goldstein FC; Zhao L; Steenland K; Levey AI; Hajjar I
    J Am Geriatr Soc; 2015 Sep; 63(9):1749-56. PubMed ID: 26389987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal study of polysomnographic variables in patients with mild cognitive impairment converting to Alzheimer's disease.
    Carnicelli L; Maestri M; Di Coscio E; Tognoni G; Fabbrini M; Schirru A; Giorgi FS; Siciliano G; Bonuccelli U; Bonanni E
    J Sleep Res; 2019 Oct; 28(5):e12821. PubMed ID: 30724408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.